Although there are several new therapeutic concepts that can be used to treat some cases of ovarian cancer, including targeted therapy involving the vascular endothelial growth factor inhibitor bevacizumab or the poly-(ADP-ribose) polymerase inhibitor olaparib25,26, ovarian cancer still causes the majority of cancer-related deaths from gynecological cancer27. This evidence concerns the gene VEGFA and ovarian carcinoma.